<ps class="kpjejo"></ps>

K8官网

Be the most trusted biotech company

2026-05-26

Globalisation 2.0 | First Patient Dosed in China for International Multi-centre Phase 1 Clinical Trial of Henlius’ Subcutaneous Daratumumab Biosimilar HLX15-SC
2026-05-26

Globalisation 2.0 | Henlius Completes First Patient Dosed in China for MRCT of pimurutamab (HLX07) Plus serplulimab, Accelerating Global Development
2026-05-25

ASCO 2026 | Henlius to Disclose Key PFS Data of PD-L1 ADC HLX43 for the First Time; Clinical Benefits in Refractory NSCLC to be Unveiled
2026-05-23

Henlius' Serplulimab Receives Positive CHMP Opinion for the Treatment of sqNSCLC
2026-05-23

Henlius' First-in-Class B7-H3–Targeted Sialidase Fusion Protein HLX316/E-688 Administered to First Patient in Phase 1 Study in China
2026-05-22

ASCO 2026: Henlius’ Serplulimab Unveils 8 Major Studies, Highlighted by the Global Debut of Perioperative Gastric Cancer Data with Significant Improvement in EFS and pCR Rate of 21.6%
2026-05-22

Henlius' STEAP1×CD3×CD28 Trispecific TCE HLX3902 Approved for Clinical Trial in Australia，Showing Potential Against Cold Tumours
2026-05-21

Henlius Announces IND Approval from NMPA for Its Proprietary c-Met/EGFR Bispecific ADC HLX48
2026-05-21

Global Development Accelerates Further: Henlius' PD-L1 ADC HLX43 Completes First Patient Dosing in EU for Phase 2 MRCT